‘Long Promised and Much Needed’ – FDA Launches Review of Abortion Pill
Oct 1, 2025 by FACT
The Department of Health and Human Services (HHS), in collaboration with the Food and Drug Administration (FDA), has finally launched a full-fledged investigation into the dangers of the abortion drug Mifepristone. This comes in response to a letter signed by 22 attorneys general urging the FDA to tighten regulations in light of a study from the Ethics and Public Policy Center (EPPC) that revealed the drug is 22x more dangerous than the FDA currently claims.
“Recent comprehensive studies of the real-world effects of the chemical abortion drug mifepristone report that serious adverse events occur 22 times more often than stated on the drug’s label, while the drug is less than half as effective as claimed. These facts directly contradict the drug’s primary marketing message of ‘safe’ and ‘effective,’” the letter reads.
In fact, the EPPC study, which is 28 times larger than all the FDA-cited clinical trials combined, concluded:
“Our research shows unequivocally that Mifepristone abortion, as currently practiced in the U.S., is considerably more dangerous to women than is represented on the FDA-approved drug label. The FDA should immediately reinstate its earlier, stronger patient safety protocols to ensure physician responsibility for women who take mifepristone under their care, as well as mandate full reporting of its side effects. The FDA should further investigate the harm this drug causes to women and, based on objective safety criteria, reconsider its approval altogether. Women deserve better than the abortion pill.”
Thankfully, the Trump administration is taking this study seriously. HHS Secretary Robert F. Kennedy Jr. announced alongside FDA Commissioner Marty Makary that their departments have initiated a thorough review of the drug and will reconsider the current safety protocols.
"HHS — through the FDA — is conducting its own review of the evidence, including real-world outcomes and evidence, relating to the safety and efficacy of the drug,” a letter from HHS to the attorneys general states. “Recent studies — such as the study by the Ethics and Public Policy Center (EPPC), which you highlighted in your letter — indicate potential dangers that may attend offering mifepristone without sufficient medical support or supervision.”
“FDA's own data collected between 2000 to 2012 indicated 2,740 adverse events, including 416 events involving blood loss requiring transfusions. Since then, safeguards for women regarding the administration of Mifepristone have been significantly reduced,” the letter continued.
Mifepristone puts women in unnecessary danger; the data leaves no room for doubt. The FDA standards must be revised in order to save women’s lives – not to mention the lives of their unborn babies.
“This FDA review of the abortion drug is long promised and much needed. Almost 70% of abortions in America are chemical abortions, and there are no meaningful safety restrictions on the drug currently in place. FDA should reinstate safety rules ASAP,” Senator Josh Hawley stated.
Praise God this issue is finally getting the attention it deserves at the national level! As we previously reported, although abortion is banned in Tennessee, we know that pharmaceutical companies are using loopholes to ship Mifepristone to women in our state, killing hundreds, if not thousands, of Tennessee babies every year. Please join us in praying that the HHS and FDA study will result in positive change for our state and nation.
“Recent comprehensive studies of the real-world effects of the chemical abortion drug mifepristone report that serious adverse events occur 22 times more often than stated on the drug’s label, while the drug is less than half as effective as claimed. These facts directly contradict the drug’s primary marketing message of ‘safe’ and ‘effective,’” the letter reads.
In fact, the EPPC study, which is 28 times larger than all the FDA-cited clinical trials combined, concluded:
“Our research shows unequivocally that Mifepristone abortion, as currently practiced in the U.S., is considerably more dangerous to women than is represented on the FDA-approved drug label. The FDA should immediately reinstate its earlier, stronger patient safety protocols to ensure physician responsibility for women who take mifepristone under their care, as well as mandate full reporting of its side effects. The FDA should further investigate the harm this drug causes to women and, based on objective safety criteria, reconsider its approval altogether. Women deserve better than the abortion pill.”
Thankfully, the Trump administration is taking this study seriously. HHS Secretary Robert F. Kennedy Jr. announced alongside FDA Commissioner Marty Makary that their departments have initiated a thorough review of the drug and will reconsider the current safety protocols.
"HHS — through the FDA — is conducting its own review of the evidence, including real-world outcomes and evidence, relating to the safety and efficacy of the drug,” a letter from HHS to the attorneys general states. “Recent studies — such as the study by the Ethics and Public Policy Center (EPPC), which you highlighted in your letter — indicate potential dangers that may attend offering mifepristone without sufficient medical support or supervision.”
“FDA's own data collected between 2000 to 2012 indicated 2,740 adverse events, including 416 events involving blood loss requiring transfusions. Since then, safeguards for women regarding the administration of Mifepristone have been significantly reduced,” the letter continued.
Mifepristone puts women in unnecessary danger; the data leaves no room for doubt. The FDA standards must be revised in order to save women’s lives – not to mention the lives of their unborn babies.
“This FDA review of the abortion drug is long promised and much needed. Almost 70% of abortions in America are chemical abortions, and there are no meaningful safety restrictions on the drug currently in place. FDA should reinstate safety rules ASAP,” Senator Josh Hawley stated.
Praise God this issue is finally getting the attention it deserves at the national level! As we previously reported, although abortion is banned in Tennessee, we know that pharmaceutical companies are using loopholes to ship Mifepristone to women in our state, killing hundreds, if not thousands, of Tennessee babies every year. Please join us in praying that the HHS and FDA study will result in positive change for our state and nation.
